Company Overview - SierraMedical, an innovative domestic ophthalmic medical device company, recently completed a new financing round exceeding 100 million yuan, led by Qianji Capital and Shunwei Capital, with existing shareholders Bohang Capital and Honghui Fund increasing their stakes [1] - Founded in July 2022, SierraMedical integrates research and development, production, and sales, focusing on providing precise and intelligent minimally invasive surgical solutions for ophthalmology [3] Product Development - The financing will primarily support the deep development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, while also enriching the company's ophthalmic surgical equipment product matrix [1] - SierraMedical has launched the NEXVIT® series of ultra-high-speed dual-blade dual-gas path vitreous cutting heads, achieving a cutting speed of up to 20,000 cuts per minute, which has been clinically validated for performance and safety [3] - The company is also developing a disposable ophthalmic puncture device that features a slanted front cut and a chamfered design to assist surgeons in making precise and safe incisions, minimizing damage to surrounding eye tissue [4] Market Potential - The ophthalmic medical device market in China reached a scale of 45 billion yuan in 2023, with a compound annual growth rate exceeding 15%, significantly higher than the global average [3] - SierraMedical aims to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector and address critical instrument supply issues [3] Investment Insight - Qianji Capital and Shunwei Capital, both leading investors in this financing round, have a strong track record in the medical field, with Qianji Capital being one of the earliest specialized funds in healthcare and life sciences in China [6]

据天眼查，思埃然医疗成立于2022年7月，是一家集研发、生产、销售为一体的创新医疗器械企业，公 司核心团队有着丰富的行业经验，具备完整的研发-生产-商业化能力，专注于为眼科提供精准智能化微 创手术治疗方案，致力于打破国外企业在高端眼科手术器械领域的垄断，解决关键手术器械"卡脖子"问 题。 来源：猎云网 9月2日，眼科医疗器械创新企业思埃然医疗完成超亿元融资，由千骥资本、顺为资本联合领投，老股东 博行资本、弘晖基金持续加注，本轮融资资金将主要用于公司首款自主研发的超乳玻切一体机产品线的 深度研发推进，同时进一步丰富公司眼科手术设备产品矩阵，加速国产高端眼科器械的进口替代和公司 眼科产品的出海进程。 目前在研产品主要包括超乳玻切一体机及其配套耗材，数字化手术显微镜等高端眼科手术器械。 截至目前，公司已完成3轮亿元级融资。 ...

Core Insights - Honghui Fund's portfolio company, Siairan, has completed over 100 million yuan financing, led by Qianji Capital and Shunwei Capital, with existing investors including Boxin Capital and Honghui Fund increasing their stakes [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine, as well as to expand the product matrix of ophthalmic surgical equipment [1] - Siairan Medical, established in July 2022, has a core team with extensive industry experience and complete capabilities in R&D, production, and commercialization [1] Company Overview - Siairan Medical focuses on providing precise and intelligent minimally invasive surgical solutions for ophthalmology, aiming to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector [1] - The company is addressing critical issues related to key surgical instruments and is currently developing products including the phacoemulsification and vitrectomy integrated machine and digital surgical microscopes [1] - Siairan Medical is committed to offering innovative and high-quality products and services to ophthalmologists and patients, promoting the advancement of ophthalmic medical technology [1]

Core Insights - SierraMedical, a leading domestic ophthalmic medical device innovation company, has successfully completed a new round of financing exceeding 100 million yuan, following a previous round in 2024 [1] - The financing was led by Qianji Capital and Shunwei Capital, with existing shareholders such as Boxin Capital and Honghui Fund also increasing their investments [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, as well as to enrich the company's ophthalmic surgical equipment product matrix [1] Company Development - SierraMedical aims to accelerate the import substitution of high-end ophthalmic instruments and the international expansion of its ophthalmic products [1] - The successful completion of this financing reflects investors' high recognition of SierraMedical's innovation capabilities and development prospects, providing strong momentum for the company's next stage of growth [1] - Established in July 2022, SierraMedical's core team possesses extensive industry experience and has complete capabilities in research, production, and commercialization [1] Industry Context - The domestic ophthalmic surgical equipment market has long relied on imported brands, but SierraMedical is gradually breaking this situation with its core proprietary technology [1] - The company focuses on providing precise and intelligent minimally invasive surgical treatment solutions for ophthalmology, aiming to break the monopoly of foreign enterprises in the high-end ophthalmic surgical instrument sector and address critical surgical instrument supply issues [1]